Citadel Advisors
KRRO icon

Citadel Advisors’s Korro Bio KRRO Stock Holding History

Citadel Advisors’s Portfolio KRRO Stock Details KRRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$787K Buy
69,500
+54,800
+373% +$603K ﹤0.01% 8226
2025
Q4 		$118K Buy
+14,700
New +$344K ﹤0.01% 11512
2024
Q1 		– Sell
-34
Closed -$1.63K – 15067
2023
Q4 		$1.63K Sell
34
-14
-29% -$461 ﹤0.01% 13799
2023
Q3 		$879 Sell
48
-160
-77% -$4.01K ﹤0.01% 13963
2023
Q2 		$3.6K Sell
208
-434
-68% -$8.42K ﹤0.01% 13679
2023
Q1 		$16.1K Sell
642
-138
-18% -$15.7K ﹤0.01% 13218
2022
Q4 		$150K Sell
780
-3,258
-81% -$335K ﹤0.01% 10606
2022
Q3 		$361K Sell
4,038
-1,622
-29% -$165K ﹤0.01% 9175
2022
Q2 		$425K Buy
5,660
+5,092
+896% +$344K ﹤0.01% 9021
2022
Q1 		$60K Buy
568
+54
+11% +$10.3K ﹤0.01% 12677
2021
Q4 		$132K Sell
514
-850
-62% -$258K ﹤0.01% 12428
2021
Q3 		$481K Sell
1,364
-306
-18% -$120K ﹤0.01% 9968
2021
Q2 		$832K Sell
1,670
-1,782
-52% -$870K ﹤0.01% 8840
2021
Q1 		$1.64M Buy
3,452
+3,256
+1,661% +$6.33M ﹤0.01% 6884
2020
Q4 		$346K Buy
+196
New +$259K ﹤0.01% 8816

Other funds holding KRRO

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Citadel Advisors's KRRO Position: Q1 2026 in Review

Citadel Advisors reduced its Korro Bio (KRRO) stake by 47% in Q1 2026, selling an estimated $302K and leaving 30,914 shares worth $350K. The position accounts for ﹤0.01% of the portfolio, ranked #10123.

Citadel Advisors first reported a position in KRRO in Q4 2019 and has held it in 22 quarters since. The position peaked at $46.4M in Q1 2024. 99 funds tracked by Wall St. Rank hold KRRO as of Q1 2026.

  • Citadel Advisors held 30,914 shares of Korro Bio worth $350K as of Q1 2026.
  • Citadel Advisors sold 27,415 Korro Bio shares in Q1 2026, an estimated $302K.
  • Korro Bio made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #10123 holding.
  • Citadel Advisors first reported a position in Korro Bio in Q4 2019 and has held it in 22 quarters since.
  • Citadel Advisors's Korro Bio position peaked at $46.4M in Q1 2024.
  • 99 funds tracked by Wall St. Rank held Korro Bio as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.